| 5930- | Catechins, | Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention |
| - | Trial, | Pca, | NA |
| 603- | Catechins, | Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species |
| - | in-vitro, | NA, | HL-60 |
| 939- | Catechins, | 5-FU, | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
| - | vitro+vivo, | GC, | SNU620 |
| 5916- | Cats, | Chemo, | Uncaria tomentosa—Adjuvant Treatment for Breast Cancer: Clinical Trial |
| - | Trial, | BC, | NA |
| 5922- | Cats, | Uncaria tomentosa acts as a potent TNF-α inhibitor through NF-κB |
| - | in-vitro, | AML, | THP1 |
| 5921- | Cats, | Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells |
| - | in-vitro, | Colon, | HT29 |
| 5917- | Cats, | Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial |
| - | Trial, | CRC, | NA |
| 5920- | Cats, | Treatment with Uncaria tomentosa Promotes Apoptosis in B16-BL6 Mouse Melanoma Cells and Inhibits the Growth of B16-BL6 Tumours |
| - | in-vivo, | Melanoma, | B16-BL6 |
| 5919- | Cats, | Cisplatin, | Uncaria tomentosa Leaves Decoction Modulates Differently ROS Production in Cancer and Normal Cells, and Effects Cisplatin Cytotoxicity |
| - | in-vitro, | Liver, | HepG2 |
| 5915- | Cats, | Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells |
| - | in-vitro, | AML, | NA |
| 5914- | Cats, | Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells |
| - | in-vitro, | AML, | HL-60 |
| 5913- | Cats, | Cat's claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection |
| - | Review, | Nor, | NA |
| 5918- | Cats, | Uncaria tomentosa (cat's claw) improves quality of life in patients with advanced solid tumors |
| - | Trial, | Var, | NA |
| 5811- | CBC, | The Potential of Cannabichromene (CBC) as a Therapeutic Agent |
| - | Review, | Var, | NA |
| 18- | CBC/D, | Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli |
| - | vitro+vivo, | MB, | NA |
| 17- | CBC/D, | CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1 |
| - | in-vivo, | CRC, | NA |
| 1103- | CBD, | Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | NA, | NA |
| 1199- | CBD, | Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis |
| - | in-vivo, | Obesity, | NA |
| 5820- | CBD, | Cannabidiol effects in stem cells: A systematic review |
| - | Review, | Var, | NA |
| 5812- | CBD, | Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis |
| - | Trial, | Var, | NA |
| 5813- | CBD, | Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis |
| - | Review, | Var, | NA |
| 5814- | CBD, | Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline |
| - | Review, | Var, | NA |
| 5815- | CBD, | Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents |
| - | in-vitro, | GBM, | NA |
| 5816- | CBD, | Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4 |
| - | in-vitro, | GBM, | NA |
| 5817- | CBD, | COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells |
| - | vitro+vivo, | Lung, | A549 |
| 5818- | CBD, | Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress |
| - | in-vivo, | PC, | PANC1 |
| 5819- | CBD, | The potential role of cannabidiol (CBD) in lung cancer therapy: a systematic review of preclinical and clinical evidence |
| - | Review, | Lung, | NA |
| 1081- | CBDA, | Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 5979- | CDT, | AgNPs, | Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions |
| - | Review, | Var, | NA |
| 5973- | CDT, | Chemodynamic Therapy via Fenton and Fenton-Like Nanomaterials: Strategies and Recent Advances |
| - | Review, | Var, | NA |
| 5974- | CDT, | Chemodynamic nanomaterials for cancer theranostics |
| - | Review, | Var, | NA |
| 5963- | CEL, | Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis |
| - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
| 5966- | CEL, | Determine whether administering celecoxib during radiotherapy can reduce the risk of recurrence of triple-negative breast cancer. Pilot study |
| - | Trial, | BC, | NA |
| 5965- | CEL, | Cisplatin, | Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway |
| - | in-vitro, | OS, | MG63 |
| 5964- | CEL, | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| - | Review, | Var, | NA |
| 5962- | CEL, | The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II |
| - | Study, | Var, | NA |
| 5961- | CEL, | Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer |
| - | Review, | Var, | NA |
| 5960- | CEL, | Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers |
| - | Trial, | Pca, | NA |
| 5959- | CEL, | Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target |
| - | in-vitro, | Cerv, | HeLa |
| 5958- | CEL, | Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition |
| - | in-vitro, | Var, | NA |
| 5957- | CEL, | Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line |
| - | in-vitro, | Colon, | HT29 |
| 5956- | CEL, | Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy |
| - | Review, | Var, | NA |
| 5955- | CEL, | COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib |
| - | in-vitro, | Colon, | NA |
| 5954- | CEL, | The molecular mechanisms of celecoxib in tumor development |
| - | Review, | Var, | NA |
| 1105- | CEL, | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis |
| - | in-vitro, | BC, | NA |
| 1054- | CEL, | Celecoxib inhibited activation of NF-κB and expression of NF-κB P65 protein in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 955- | CEL, | Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells |
| - | in-vitro, | RPE, | D407 |
| 5953- | Cela, | CUR, | The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis |
| - | vitro+vivo, | NPC, | NA |
| 5939- | Cela, | Chemo, | Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells |
| - | in-vitro, | Melanoma, | U266 | - | in-vitro, | Melanoma, | RPMI-8226 |
| 5938- | Cela, | Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid